NCT02193698View on ClinicalTrials.gov

Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

April 30, 2016

Conditions
POEMS Syndrome
Interventions
DRUG

Lenalidomide+Dexamethasone

Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)

Trial Locations (1)

260-8760

Chiba University Graduate School of Medicine Department of neurology, Chiba

All Listed Sponsors
lead

Chiba University

OTHER

NCT02193698 - Efficacy and Safety of Lenalidomide as a Treatment for Recurrent or Refractory POEMS Syndrome Trial | Biotech Hunter | Biotech Hunter